Study tests safety and dosing of CA9hu-1 for advanced cancers
Part of Cancer, Lungs & breathing, Skin clinical trials.
This Phase 1 study tests whether CA9hu-1 is safe and what dosing schedule is appropriate for people with advanced solid tumors that have not responded to standard treatment. If you qualify, you would be monitored closely for side effects and how your body handles the medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid cancer type (such as kidney, breast, head and neck, lung, or mesothelioma) that is not responding to standard treatments (or standard options aren’t suitable).
- Your cancer is advanced and you can expect to live at least 12 weeks.
- Your overall health score (WHO performance status) is 0 or 1, meaning you’re able to do most usual activities.
- Your blood counts and organ tests must be within safe ranges (for example hemoglobin, white cells, platelets, bilirubin, and liver enzymes) done within about 1 week before the first infusion.
- Your kidneys must work enough for treatment (creatinine or isotope clearance ≥ 50 mL/min), and your clotting tests (PT/APTT) must be acceptable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests 9MW2821 in people with advanced solid cancers that have grown despite earlier treatment. It aims to find the safest dose and learn how the drug works, and it may be an option if you can provide tumor tissue and meet key health criteria.
This trial tests if the investigational drug BNT329 is safe and could help people with advanced solid tumors that make a marker called CA19-9. It is for those who have tried standard treatments and need new options.
This trial tests a new drug, HY0001a, for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein on some cancer cells, and the study aims to find the right dose and see if it helps shrink tumors.
This trial tests a new drug called MHB009C for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
This Phase 1 study tests how safe INCA33890 is in adults with advanced or metastatic solid cancers. Because it’s an early safety study, the main goal is to see how the body handles the drug and whether it causes side effects.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.